Key Highlights
- Revenue was USD 5.0 million against an estimate of no revenue.
- Loss per share was USD 0.81 against an estimate of a USD 1.05 loss.
- Net loss was USD 40.31 million, against USD 34.98 million a year earlier.
- Cash was USD 113.58 million and short-term investments were USD 279.64 million.
ArriVent BioPharma (NASDAQ:AVBP) reported third quarter 2026 Revenue of USD 5.0 million, against an estimate of no revenue. The loss per share was USD 0.81, compared with an estimate of a USD 1.05 loss and a USD 0.83 loss in the third quarter of 2025.
Net loss was USD 40.31 million, compared with USD 34.98 million in the prior-year quarter. The operating loss was USD 43.38 million, against USD 38.32 million. The company reported the figures in its quarterly filing for the period ended September 30, 2026.
Operating Expenses
Research and development expenses were USD 38.90 million, compared with USD 32.17 million, an increase of USD 6.7 million. The filing attributes the increase primarily to a USD 5.1 million increase in costs related to early-stage programs, driven by the achievement of certain development milestones, and a USD 1.3 million increase in personnel-related costs due to increased headcount.
General and administrative expenses were USD 9.48 million, compared with USD 6.15 million. Total operating expenses were USD 48.38 million, against USD 38.32 million. Interest and Investment income was USD 3.06 million, against USD 3.34 million.
Nine-Month Results
For the nine months ended September 30, 2026, total operating expenses were USD 147.18 million, against USD 138.71 million. The operating loss was USD 142.18 million, compared with USD 138.71 million, and net loss was USD 133.53 million, compared with USD 130.76 million.
The nine-month loss per share was USD 2.82, against USD 3.54. Research and Development expenses for the nine months were USD 118.85 million, against USD 121.18 million, while general and administrative expenses were USD 28.32 million, against USD 17.54 million.
Programs, Licenses and Liquidity
The filing describes ARR-217, also known as MRG007, as a cadherin-17 targeted antibody-drug conjugate with a glycan-linked, exatecan-based linker-payload, being evaluated in a Phase 1 clinical trial of gastrointestinal tumors. The company entered into a license agreement with Shanghai Allist Pharmaceuticals in June 2021 and a license agreement with Lepu Biopharma in January 2025. Amounts received before performance are recorded as deferred revenue.
Cash and cash equivalents were USD 113.58 million at September 30, 2026, compared with USD 45.54 million at the prior Balance Sheet date, and short-term investments were USD 279.64 million, compared with USD 267.28 million. The company's cash, cash equivalents and investments consist of cash held in an interest-bearing savings account, Money Market funds, and corporate and government Debt securities with contractual maturities of less than one year.
ArriVent BioPharma Q3 2026 Earnings: Key Takeaways
ArriVent BioPharma reported third quarter 2026 revenue of USD 5.0 million and a loss per share of USD 0.81. Net loss was USD 40.31 million, research and development expenses were USD 38.90 million, and short-term investments were USD 279.64 million.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...